Visão geral da empresa
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects individuals directly to licensed healthcare professionals across multiple international markets, including the United States, United Kingdom, Canada, Germany, Ireland, France, Spain, and beyond. This business model positions the entity within the broader Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which typically involves the development, manufacturing, and distribution of pharmaceutical products for specific therapeutic areas. The company demonstrates significant scale with a total market capitalization of $4.42 billion, generating annual revenue of $2.35 billion, and employing a workforce of 2,442 individuals. These financial dimensions indicate that the organization has established a substantial footprint in the digital health landscape, supported by a robust infrastructure capable of serving a global customer base while maintaining a valuation that reflects strong investor confidence in its operational model and growth potential within the specialty drug manufacturing niche.
Saúde financeira
The company reported revenue of $2.35 billion over the trailing twelve months, with a net income of $128.37 million and EBITDA reaching $175.66 million. The notable gap between the $2.35 billion in revenue and the $128.37 million in net income highlights a cost structure where operating expenses, likely including significant sales, general, and administrative costs, absorb a considerable portion of top-line growth before reaching the bottom line. Despite this, the business generates $110.51 million in free cash flow, which provides a critical buffer for financial flexibility, allowing management to fund operations, invest in technology, or manage capital allocation without relying solely on external financing. Profitability is further contextualized by three distinct margin metrics: a gross margin of 73.8% indicates high efficiency in production and supply chain management relative to the cost of goods sold; however, an operating margin of 2.7% suggests that operational overheads are substantial, while the final profit margin of 5.5% reflects the comprehensive impact of all expenses on earnings. Regarding liquidity and leverage, the balance sheet shows $577.49 million in cash against $1.12 billion in total debt, resulting in a debt-to-equity ratio of 207.16, which characterizes the capital structure as highly leveraged. Short-term solvency is supported by a current ratio of 1.90, indicating that the company holds nearly twice the value of current assets compared to current liabilities, ensuring adequate liquidity to meet obligations. Return metrics reveal that the Return on Equity stands at 25.2%, signaling highly effective deployment of shareholder capital, whereas the Return on Assets of 5.3% indicates a lower efficiency in generating profits from the total asset base, a dynamic often seen in capital-intensive or highly leveraged business models.
Avaliação de valorização
Valuation multiples show a trailing P/E ratio of 38.02 and a forward P/E of 13.66, implying that the market expects a significant improvement in earnings trajectory, as the forward multiple is nearly three times lower than the trailing multiple. The price-to-book ratio is recorded at 8.15, indicating that the company trades at a substantial premium over its book value, reflecting market expectations of future growth that exceed the current asset base. Alternative valuation measures, including a price-to-sales ratio of 1.88 and an EV/EBITDA of 28.25, suggest that investors are willing to pay a high multiple for revenue and earnings, consistent with high-growth biotech or specialty drug profiles. Price momentum is observed within a 52-week range bounded by a high of $70.43 and a low of $13.74, placing the current trading price significantly below the annual peak and well above the recent floor. The stock exhibits a beta of 2.31, which means its price volatility is more than twice that of the broader market, indicating a high-risk profile suitable for investors with a higher tolerance for price swings in exchange for potential asymmetric returns.
Growth & Income
Revenue growth accelerated to 28.4% year-over-year, while earnings growth declined by 17.4% year-over-year, revealing that profitability is currently lagging behind top-line expansion, likely due to the high operating expenses noted in the margin analysis. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all of its earnings to reinvest into business growth, R&D, or debt reduction rather than distributing income to shareholders. This reinvestment strategy aligns with the high debt-to-equity ratio, suggesting capital is being directed toward strengthening the balance sheet or funding expansion initiatives rather than providing immediate income to investors. Overall, the growth and income profile is characterized by rapid revenue expansion and a complete retention of earnings, prioritizing capital appreciation and business scaling over current cash yield.